Last reviewed · How we verify
PrabotulinumtoxinA-Xvfs
PrabotulinumtoxinA-Xvfs is a Botulinum toxin type A Small molecule drug developed by Lupo Center for Aesthetic and General Dermatology. It is currently FDA-approved for Aesthetic treatment of facial wrinkles and expression lines, Cosmetic facial rejuvenation. Also known as: Jeaveau, Jeuveau.
PrabotulinumtoxinA-Xvfs is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
PrabotulinumtoxinA-Xvfs is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Aesthetic treatment of facial wrinkles and expression lines, Cosmetic facial rejuvenation.
At a glance
| Generic name | PrabotulinumtoxinA-Xvfs |
|---|---|
| Also known as | Jeaveau, Jeuveau |
| Sponsor | Lupo Center for Aesthetic and General Dermatology |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (acetylcholine release machinery) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Aesthetics |
| Phase | FDA-approved |
Mechanism of action
This drug is a purified botulinum toxin serotype A that cleaves SNARE proteins required for acetylcholine vesicle release. By preventing neurotransmitter release at motor nerve terminals, it induces temporary flaccid paralysis of injected muscles. The effect is reversible as new neuromuscular junctions form over several months.
Approved indications
- Aesthetic treatment of facial wrinkles and expression lines
- Cosmetic facial rejuvenation
Common side effects
- Injection site reactions (erythema, edema, bruising)
- Headache
- Muscle weakness or drooping
- Eyelid ptosis
Key clinical trials
- Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture (PHASE1)
- BoTox Into the Sternocleidomastoid Muscles (SCM) (PHASE4)
- Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines (PHASE2)
- Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PrabotulinumtoxinA-Xvfs CI brief — competitive landscape report
- PrabotulinumtoxinA-Xvfs updates RSS · CI watch RSS
- Lupo Center for Aesthetic and General Dermatology portfolio CI
Frequently asked questions about PrabotulinumtoxinA-Xvfs
What is PrabotulinumtoxinA-Xvfs?
How does PrabotulinumtoxinA-Xvfs work?
What is PrabotulinumtoxinA-Xvfs used for?
Who makes PrabotulinumtoxinA-Xvfs?
Is PrabotulinumtoxinA-Xvfs also known as anything else?
What drug class is PrabotulinumtoxinA-Xvfs in?
What development phase is PrabotulinumtoxinA-Xvfs in?
What are the side effects of PrabotulinumtoxinA-Xvfs?
What does PrabotulinumtoxinA-Xvfs target?
Related
- Drug class: All Botulinum toxin type A drugs
- Target: All drugs targeting SNARE complex (acetylcholine release machinery)
- Manufacturer: Lupo Center for Aesthetic and General Dermatology — full pipeline
- Therapeutic area: All drugs in Dermatology / Aesthetics
- Indication: Drugs for Aesthetic treatment of facial wrinkles and expression lines
- Indication: Drugs for Cosmetic facial rejuvenation
- Also known as: Jeaveau, Jeuveau